Clinical trials: Refractory Schizophrenia
Schizophrenia
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
- Trial name
- ATHSCHIZ (NCT05623228)
- Testing
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Rakitzi, Stavroula
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.
- Trial name
- NCT00042224
- Testing
- Electroconvulsive Therapy (ECT), Clozapine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Northwell Health
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
D-serine Monotherapy for Schizophrenia
A first generation of clinical studies, performed during the last decade, demonstrates that adjuvant treatment with compounds that enhance NMDAR-mediated neurotransmission due to their agonistic activity at the NMDAR-associated…
- Trial name
- NCT00816894
- Testing
- D-serine, Olanzapine
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Herzog Hospital
Schizophrenia
Treating Refractory Schizophrenia With rTMS
Symptomatic treatment of the negative symptoms in schizophrenia (such as social withdrawal, affective flattening, poor motivation, and apathy) with medications and psychotherapy are almost non-existent, whereas treatment of the…
- Trial name
- NCT02242578
- Testing
- 1 Hz rTMS, 10 Hz rTMS
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Seton Healthcare Family
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan
Schizophrenia
Evaluation of the Role of Neurodegeneration in Schizophrenia
Schizophrenia is a progressive psychiatric disorder with a lifetime prevalence of 1%, its etiology is not fully understood, and it progresses with relapses.
- Trial name
- NCT05257720
- Testing
- GFAP, S100B
- Where
- Turkey (Türkiye)
- Volunteers
- 178 people
- Sponsor
- Istanbul Saglik Bilimleri University
Treatment Resistant Schizophrenia
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%.
- Trial name
- NCT05944510
- Testing
- Dextromethorphan
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Treating Drug-Resistant Childhood Schizophrenia
This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia.
- Trial name
- NCT00048828
- Testing
- Olanzapine, Clozapine
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Northwell Health
Depressive Disorder, Schizophrenia
Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder
Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD).
- Conditions
- Depressive Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder
- Trial name
- NCT01596608
- Testing
- Magnetic Seizure Therapy (MagPro MST)
- Where
- Canada
- Volunteers
- 224 people
- Sponsor
- Centre for Addiction and Mental Health
Hallucinations, Schizophrenia
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study…
- Conditions
- Hallucinations, Schizophrenia, Perceptual Disorders
- Trial name
- MULTIMODHAL (NCT01373866)
- Testing
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Lille
Schizophrenia Negative Type
Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study
The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant…
- Trial name
- NCT07485751
- Testing
- hDFSCs-Exo
- Volunteers
- 15 people
- Sponsor
- Zigong Mental Health Center
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia
D-serine in Schizophrenia
This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.
- Trial name
- DSRSZ (NCT03702933)
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Herzog Hospital
Schizophrenia
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00154258
- Testing
- Clozapine
- Volunteers
- 19 people
- Sponsor
- Novartis
Treatment-resistant Schizophrenia
Deep Brain Stimulation in Treatment Resistant Schizophrenia
The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia.
- Trial name
- NCT02361554
- Testing
- Medtronic Percept with SensSight Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University